BACKGROUND: There is a paucity of data describing the sustained benefits of lifestyle interventions on health behaviors and blood pressure (BP). METHODS: We examined the persistence of changes in health habits and BP in the ENCORE study, a trial in which 144 overweight individuals with above-normal BP were randomized to one of the following 16-week interventions: Dietary Approaches to Stop Hypertension (DASH) diet alone (DASH-A), DASH diet plus a behavioral weight management intervention (DASH-WM), or Usual Care. Follow-up assessments were conducted 8 months after the end of treatment. RESULTS: At 16 weeks, systolic BP was reduced by 16.1 (95% confidence interval (CI) = 13.0-19.2) mm Hg in the DASH-WM group, 11.2 (95% CI = 8.1-14.3) mm Hg in the DASH-A group, and 3.4 (95% CI = 0.4-6.4) mm Hg in the Usual Care group. A decrease in BP persisted for 8 months, with systolic BP lower than baseline by 11.7 (95% CI = 8.1-15.3) mm Hg in the DASH-WM group, 9.5 (95% CI = 6.7-12.1) mm Hg in the DASH-A group, and 3.9 (95% CI = 0.5-7.3) mm Hg in the Usual Care group (P < 0.001 for active treatments vs. Usual Care). DASH-WM subjects lost 8.7 kg during the intervention and remained 6.3 kg lighter on follow-up examination. Changes in diet content were sustained in both DASH intervention groups. Among those who participated in DASH-WM, however, caloric intake was no longer lower, and only 21% reported still exercising regularly 8 months after completing the intervention. CONCLUSIONS: Changes in dietary habits, weight, and BP persisted for 8 months after completion of the 16-week ENCORE program, with some attenuation of the benefits. Additional research is needed to identify effective methods to promote long-term maintenance of the benefits of lifestyle modification programs. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT00571844.
RCT Entities:
BACKGROUND: There is a paucity of data describing the sustained benefits of lifestyle interventions on health behaviors and blood pressure (BP). METHODS: We examined the persistence of changes in health habits and BP in the ENCORE study, a trial in which 144 overweight individuals with above-normal BP were randomized to one of the following 16-week interventions: Dietary Approaches to Stop Hypertension (DASH) diet alone (DASH-A), DASH diet plus a behavioral weight management intervention (DASH-WM), or Usual Care. Follow-up assessments were conducted 8 months after the end of treatment. RESULTS: At 16 weeks, systolic BP was reduced by 16.1 (95% confidence interval (CI) = 13.0-19.2) mm Hg in the DASH-WM group, 11.2 (95% CI = 8.1-14.3) mm Hg in the DASH-A group, and 3.4 (95% CI = 0.4-6.4) mm Hg in the Usual Care group. A decrease in BP persisted for 8 months, with systolic BP lower than baseline by 11.7 (95% CI = 8.1-15.3) mm Hg in the DASH-WM group, 9.5 (95% CI = 6.7-12.1) mm Hg in the DASH-A group, and 3.9 (95% CI = 0.5-7.3) mm Hg in the Usual Care group (P < 0.001 for active treatments vs. Usual Care). DASH-WM subjects lost 8.7 kg during the intervention and remained 6.3 kg lighter on follow-up examination. Changes in diet content were sustained in both DASH intervention groups. Among those who participated in DASH-WM, however, caloric intake was no longer lower, and only 21% reported still exercising regularly 8 months after completing the intervention. CONCLUSIONS: Changes in dietary habits, weight, and BP persisted for 8 months after completion of the 16-week ENCORE program, with some attenuation of the benefits. Additional research is needed to identify effective methods to promote long-term maintenance of the benefits of lifestyle modification programs. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT00571844.
Authors: Lawrence J Appel; Catherine M Champagne; David W Harsha; Lawton S Cooper; Eva Obarzanek; Patricia J Elmer; Victor J Stevens; William M Vollmer; Pao-Hwa Lin; Laura P Svetkey; Sarah W Stedman; Deborah R Young Journal: JAMA Date: 2003 Apr 23-30 Impact factor: 56.272
Authors: V J Stevens; E Obarzanek; N R Cook; I M Lee; L J Appel; D Smith West; N C Milas; M Mattfeldt-Beman; L Belden; C Bragg; M Millstone; J Raczynski; A Brewer; B Singh; J Cohen Journal: Ann Intern Med Date: 2001-01-02 Impact factor: 25.391
Authors: J A Blumenthal; A Sherwood; E C Gullette; M Babyak; R Waugh; A Georgiades; L W Craighead; D Tweedy; M Feinglos; M Appelbaum; J Hayano; A Hinderliter Journal: Arch Intern Med Date: 2000-07-10
Authors: Bonnie Spring; Jennifer M Duncan; E Amy Janke; Andrea T Kozak; H Gene McFadden; Andrew DeMott; Alex Pictor; Leonard H Epstein; Juned Siddique; Christine A Pellegrini; Joanna Buscemi; Donald Hedeker Journal: JAMA Intern Med Date: 2013-01-28 Impact factor: 21.873
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Stephanie A P Schuette; Evelyn Cordero; Katherine Slosburg; Elizabeth L Addington; David Victorson Journal: Am J Lifestyle Med Date: 2017-05-05
Authors: Pedro L Valenzuela; Pedro Carrera-Bastos; Beatriz G Gálvez; Gema Ruiz-Hurtado; José M Ordovas; Luis M Ruilope; Alejandro Lucia Journal: Nat Rev Cardiol Date: 2020-10-09 Impact factor: 32.419
Authors: James A Blumenthal; Bryan J Feger; Patrick J Smith; Lana L Watkins; Wei Jiang; Jonathan Davidson; Benson M Hoffman; Megan Ashworth; Stephanie K Mabe; Michael A Babyak; William E Kraus; Alan Hinderliter; Andrew Sherwood Journal: Am Heart J Date: 2016-03-12 Impact factor: 4.749
Authors: James A Blumenthal; Andrew Sherwood; Patrick J Smith; Stephanie Mabe; Lana Watkins; Pao-Hwa Lin; Linda W Craighead; Michael Babyak; Crystal Tyson; Kenlyn Young; Megan Ashworth; William Kraus; Lawrence Liao; Alan Hinderliter Journal: Am Heart J Date: 2015-08-14 Impact factor: 4.749